What is Capricor Therapeutics's D&A?

Capricor Therapeutics (CAPR) reported D&A of $534.67K in Q1 2026.

How has Capricor Therapeutics's D&A changed year-over-year?

Capricor Therapeutics's D&A increased by 31.9% year-over-year, from $405.45K to $534.67K.

What is the long-term trend for Capricor Therapeutics's D&A?

Over 4 years (2021 to 2025), Capricor Therapeutics's D&A has grown at a 66.5% compound annual growth rate (CAGR), from $245.7K to $1.89M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Capricor Therapeutics CAPR D&A

D&A at other companies

PfizerPFE

$1.61B-0.3%

Sarepta Therapeutics, Inc.SRPT

$10.59M+6.2%

PTC TherapeuticsPTCT

$15.41M+113%

Celldex TherapeuticsCLDX

$854K-1.5%

VericelVCEL

$3.27M+21.6%

Dyne Therapeutics, Inc.DYN

$550K+9.6%

Other financials

Income statement

See full

Revenue--100%

Operating income-$36.8M-47.2%

Net income-$33.9M-39.2%

EPS (diluted)-$0.59-11.3%

Balance sheet

See full

Cash & equivalents$105.4M+266%

Total debt$14.8M+1,083%

Total equity$278.7M+118%

Total assets$326.3M+112%

Cash flow

See full

Operating cash flow-$29.3M-355%

CapEx$5.1M+472%

Free cash flow-$34.4M-369%

Valuation

See full

Market cap$1.71B+303%

Profitability

See full

Operating margin-778.8%-1,038pp

Net margin-736.6%-981pp

FCF margin-563.9%-954pp

Returns & leverage

See full

Return on equity-56.4%-11.3pp

Debt / equity0.1×0.0×

Current ratio8.4×+1.9×

Where this comes from

Reported directly by Capricor Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Capricor Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Capricor Therapeutics's D&A?: Capricor Therapeutics (CAPR) reported D&A of $534.67K in Q1 2026.
How has Capricor Therapeutics's D&A changed year-over-year?: Capricor Therapeutics's D&A increased by 31.9% year-over-year, from $405.45K to $534.67K.
What is the long-term trend for Capricor Therapeutics's D&A?: Over 4 years (2021 to 2025), Capricor Therapeutics's D&A has grown at a 66.5% compound annual growth rate (CAGR), from $245.7K to $1.89M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.